Clinical Trials Logo

Clinical Trial Summary

Immunogenicity and Safety of V260 in Healthy Infants in Korea


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00166517
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 3
Start date August 2005
Completion date July 2006

See also
  Status Clinical Trial Phase
Completed NCT02907216 - Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Phase 4
Completed NCT00496054 - Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021) Phase 3
Completed NCT03587389 - Response to Rotavirus Vaccine in Infants in Ho Chi Minh City in Vietnam Phase 4
Unknown status NCT02177799 - Surveillance Study of Acute Gastroenteritis in Hospitalized Children in Rural Area in Lebanon N/A
Completed NCT01871038 - Rotarix Vaccine Effectiveness N/A
Completed NCT03031743 - The Influence of the Microbiome on Rotavirus Vaccine Immunogenic Response in Infants in Karachi, Pakistan N/A
Terminated NCT00836498 - A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027) Phase 1
Completed NCT02141204 - Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants Phase 3
Enrolling by invitation NCT02153866 - The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Phase 4
Completed NCT00820261 - Molecular Epidemiology of Rotavirus Diarrhea Among Infants and Young Children Attending Maua Methodist Hospital, Kenya N/A
Completed NCT00718237 - Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED) Phase 3